Welcome to our dedicated page for LKYSD news (Ticker: LKYSD), a resource for investors and traders seeking the latest updates and insights on LKYSD stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect LKYSD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of LKYSD's position in the market.
Numinus Wellness Inc. has received conditional approval from the Toronto Stock Exchange to graduate its listing from the TSX Venture Exchange. This milestone aims to enhance the company's corporate profile and investor reach. CEO Payton Nyquvest highlighted ongoing expansions in clinic networks and lab capabilities, along with strategic investments in clinical research. Final approval depends on meeting customary TSX conditions, with a timeline for graduation to be announced. The company will continue trading under the symbol 'NUMI'.
Numinus Wellness Inc. announced the departure of former Chief Strategy Officer, Stacey Wallin, after three years of service. The company will issue 2,000,000 common shares to Wallin as part of her separation agreement. CEO Payton Nyquvest expressed gratitude for Wallin's contributions and highlighted the company's commitment to its mission of advancing psychedelic-assisted therapies for mental health. Numinus aims to integrate these therapies into mainstream practice, targeting conditions such as depression and anxiety.
Numinus Wellness Inc. (TSXV: NUMI) plans to release its financial results for the quarter and year ending August 31, 2021, on December 9, 2021, after market close. A conference call and webcast will follow at 5:30 p.m. Eastern time, where executives will discuss the company's performance and initiatives. Interested participants can join via a toll-free number or a live webcast. A replay will be available until December 16, 2021. Numinus focuses on innovative mental health care and psychedelic-assisted therapies to aid individuals in healing from various mental health conditions.
Numinus Wellness Inc. (TSXV: NUMI) will change its OTC Pink market ticker symbol to NUMIF from LKYSF on November 22, 2021, enhancing alignment with its TSX-V listing. The company has also gained DTC Eligibility, allowing its shares to be electronically cleared and settled. This move is seen as a critical first step in expanding its U.S. capital markets strategy, according to CEO Payton Nyquvest. Numinus aims to transform mental health care by integrating psychedelic-assisted therapies into mainstream practice.
Numinus Wellness has announced the management of two new clinics in Montreal and Vancouver for hosting the MAPS PBC study on MDMA-assisted therapy for PTSD. This study, titled MAPPUSX, aims to evaluate the safety and efficacy of MDMA therapy. Numinus’s clinics comply with Health Canada regulations and will provide necessary therapy during the trial. Previous studies showed promising results, with 88% of participants experiencing symptom relief. The initiative is part of expanding treatment options for PTSD and enhancing collaboration with MAPS.
Numinus Wellness (TSXV: NUMI) announces participation in two upcoming events hosted by Microdose. The first event, Psychedelic Capital, is on October 28, 2021, featuring CEO Payton Nyquvest presenting at 1:45 p.m. ET. The second, Wonderland: Miami, occurs on November 8-9, 2021, with presentations by Nyquvest and Dr. Evan Lewis on November 8 and participation by Sharan Sidhu on November 9. For more details, visit www.numinus.com.
Numinus Wellness has finalized the design and protocol for a Phase 1 clinical trial of its natural Psilocybin extract, PSYBINA™, aiming to assess safety and bioavailability. The trial, named HOPE, compares PSYBINA RX™ with synthetic Psilocybin in 14 healthy volunteers at Numinus’ Vancouver site. This milestone supports Numinus’ innovative approach in psychedelic medicine, leveraging patent-pending technology to enhance product stability and production efficiency, thereby potentially lowering costs and increasing accessibility to psychedelic therapies.
Numinus Wellness (TSXV: NUMI) announced the expansion of its psychedelics research facility with an additional lab and a federal license application. This move aims to broaden its contract services, enhancing revenue streams by offering bioanalytical testing and research on psychedelics like ketamine and LSD. The new lab will double the company's research footprint and is expected to be operational by Summer 2022, allowing Numinus to support industry research more effectively. This expansion addresses the growing demand for clinical-grade materials in the psychedelics sector.
Numinus Wellness Inc. has successfully acquired the Neurology Centre of Toronto (NCT), enhancing its portfolio in mental health treatment through psychedelic-assisted therapies. The acquisition, valued at $1 million, involves $300,000 in cash and $200,000 in shares, with potential future performance-based payments. NCT will now operate as 'NCT by Numinus' under Dr. Evan Lewis, promoting integrated care for neurological conditions and mental health. This strategic move aims to expand Numinus' reach into Ontario, which will bolster its patient base and revenue potential.
Numinus Wellness Inc. (TSXV: NUMI), a leader in mental health care using psychedelic-assisted therapies, will participate in two virtual investor conferences in September 2021. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where CEO Payton Nyquvest will provide an on-demand presentation starting September 13 at 7:00 a.m. ET. The second is the Cantor Fitzgerald Global Healthcare Conference from September 27-30, featuring a live presentation on September 27 at 2:00 p.m. ET. For more details, visit Numinus Wellness.
